Evaluation of a Commercialized In Situ Hybridization Assay for Detecting Human Papillomavirus DNA in Tissue Specimens from Patients with Cervical Intraepithelial Neoplasia and Cervical Carcinoma

ABSTRACT To evaluate a commercialized in situ hybridization (ISH) assay for detecting human papillomavirus (HPV) DNA, we compared the ability of a new ISH probe, Inform HPV III (Ventana Medical Systems, Tucson, AZ), to that of PCR assays to detect HPV DNA in cervical tissue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases; CIN 2, 28 cases; and CIN 3, 33 cases), and cervical carcinoma (29 cases). General HPV DNA was detected using consensus primer-mediated PCR assays. HPV genotyping was performed by using EasyChip HPV blot (King Car Yuan Shan Institute, I-Lan, Taiwan). HPV16 integration status (E2/E6 ratio) was determined by using quantitative real-time PCR. Our findings showed that the ISH and PCR had fair to good agreements in detecting HPV DNA across all CIN categories without significant differences (Kappa coefficient, 0.34 to 0.63; P = 0.13 to 1.0). However, ISH detected significantly fewer HPV-positive cases in carcinoma than PCR did (Kappa coefficient, 0.2; P = 0.03). Eleven cases with ISH− PCR+ results had HPV types that can be detected by Inform HPV III. Five carcinoma cases with ISH− PCR+ results showed a significantly higher level of integrated HPV16 (P = 0.008) than did the ISH+ cases. As a consequence, lower copy numbers of episomal HPV16 in carcinoma might be the cause for the false-negative ISH results. Although the punctate signal pattern of HPV significantly increased with the severity of disease (P trend = 0.01), no significant difference in the HPV16 integration status was observed between the cases with a punctate signal only and the cases with mixed punctate and diffuse signals (P = 0.4). In conclusion, ISH using the Inform HPV III probe seems comparable to PCR for detecting HPV DNA in cervical tissue with CINs. False-negative ISH results appear to be associated with the lower copy numbers of the episomal HPV16 but not with the ability of the Inform HPV III probe to detect specific HPV types. In addition, signal patterns, especially a mixed punctate and diffuse pattern of HPV, cannot be reliably used to predict viral integration status.

[1]  Chien-Jen Chen,et al.  Quality assurance of genotyping array for detection and typing of human papillomavirus. , 2007, Journal of virological methods.

[2]  N. Sneige,et al.  Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma , 2007, Modern Pathology.

[3]  M. Troxell,et al.  p16INK4A Immunohistochemistry is Superior to HPV In Situ Hybridization for the Detection of High-risk HPV in Atypical Squamous Metaplasia , 2007, The American journal of surgical pathology.

[4]  Shih-hung Huang,et al.  Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. , 2006, Gynecologic oncology.

[5]  M. Stanley,et al.  Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Smedts,et al.  HPV in situ hybridization: Impact of different protocols on the detection of integrated HPV , 2005, International journal of cancer.

[7]  U. Gyllensten,et al.  Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN) , 2005, British Journal of Cancer.

[8]  M. Mukai,et al.  Comparison Between In Situ Hybridization and Real-time PCR Technique as a Means of Detecting the Integrated Form of Human Papillomavirus 16 in Cervical Neoplasia , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  A. Ferenczy,et al.  High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV , 2005, AIDS.

[10]  S. Jukić,et al.  Comparison of polymerase chain reaction and catalyzed signal amplification in situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical preneoplastic and neoplastic lesions. , 2004, Archives of medical research.

[11]  M. Martino,et al.  2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. , 2004, American journal of obstetrics and gynecology.

[12]  A. Staudach,et al.  Comparison of Real-Time PCR Signal-Amplified In Situ Hybridization and Conventional PCR for Detection and Quantification of Human Papillomavirus in Archival Cervical Cancer Tissue , 2004, Journal of Clinical Microbiology.

[13]  A. Giuliano,et al.  Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types. , 2004, The Journal of molecular diagnostics : JMD.

[14]  Pei-Hsin Chen,et al.  Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  E. Kubista,et al.  Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. , 2004, Gynecologic oncology.

[16]  David I. Smith,et al.  Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes , 2004, Cancer Research.

[17]  J. T. Cox,et al.  Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening , 2004, Obstetrics and gynecology.

[18]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[19]  K. Cooper,et al.  Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial Neoplasia , 2002, Modern Pathology.

[20]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[21]  D. Mandal,et al.  Persistant human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN) , 2002, International journal of cancer.

[22]  S. Syrjänen,et al.  Integrated Human Papillomavirus Type 16 Is Frequently Found in Cervical Cancer Precursors as Demonstrated by a Novel Quantitative Real-Time PCR Technique , 2002, Journal of Clinical Microbiology.

[23]  J. Kolberg,et al.  Single-copy Gene Detection Using Branched DNA (bDNA) In Situ Hybridization , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[24]  C. Meijer,et al.  Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia , 2001, British Journal of Cancer.

[25]  Y. Nagai,et al.  Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? , 2000, Gynecologic oncology.

[26]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[27]  M. von Knebel Doeberitz,et al.  Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. , 1999, Cancer research.

[28]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[29]  R. Tubbs,et al.  Detection of human papillomavirus in cervical carcinoma: comparison of peroxidase, Nanogold, and catalyzed reporter deposition (CARD)-Nanogold in situ hybridization. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[30]  R. Tubbs,et al.  Correspondence re: Sano T, Hikino T, Niwa Y, Kashiwabara K, Oyama T, Fukuda T, Nakajima T. In situ hybridization with biotinylated tyramide amplification: detection of human papillomavirus DNA in cervical neoplastic lesions. Mod Pathol 1998;11:19-23. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[31]  Daisy R. Lee,et al.  Detection of Human Papillomavirus in Archival Tissues: Comparison of In Situ Hybridization and Polymerase Chain Reaction , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  R. Lloyd,et al.  In Situ Hybridization Detection of Low Copy Nucleic Acid Sequences Using Catalyzed Reporter Deposition and Its Usefulness in Clinical Human Papillomavirus Typing , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[33]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[34]  H. Hollema,et al.  Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas , 1996, Journal of clinical microbiology.

[35]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[36]  K. Cooper,et al.  Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation. , 1991, Journal of clinical pathology.

[37]  A. Reingold,et al.  Genital human papillomavirus infection in female university students as determined by a PCR‐based method , 1991, JAMA.

[38]  P. Chan,et al.  Biases in human papillomavirus genotype prevalence assessment associatedwith commonly used consensus primers , 2006, International journal of cancer.

[39]  T. Nakajima,et al.  In situ hybridization with biotinylated tyramide amplification: detection of human papillomavirus DNA in cervical neoplastic lesions. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.